BioPharma Dive November 13, 2024
Kristin Jensen

With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of obesity treatments.

Dive Brief:

  • Metsera, already a well-funded biotech startup, added another $215 million to its coffers as investors responded to the promise of its obesity drug pipeline.
  • Wellington Management and Venrock Healthcare Capital Partners led the latest round of financing, the company said Wednesday. New investors included “crossover” investors such as Fidelity Management & Research, Janus Henderson Investors and T. Rowe Price.
  • The Series B financing brings the total raised for Metsera to more than $500 million. The company officially launched in April after raising $290 million in a financing led by Arch Venture Partners and Population Health...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Related Articles:
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected
NIH's unfinished business
Lilly blames slower-than-expected growth for 2024 sales miss
AbbVie to write off $3.5B over failed schizophrenia drug

Share This Article